Appili Ther Stock Price, News & Analysis

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) announced that Dr. Don Cilla, President and CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 26, 2023, in Toronto. The presentation will highlight updates on Appili's pipeline, including ATI-1701, a tularemia vaccine funded by the U.S. Government, and ATI-1801, a treatment for cutaneous leishmaniasis. Both programs may qualify for FDA Priority Review Vouchers upon approval. The conference will include one-on-one meetings for investors. Appili Therapeutics focuses on developing novel anti-infectives to combat life-threatening infections.

Appili Therapeutics has appointed Dr. Gary Nabors as Chief Development Officer effective April 3, 2023. With over 25 years of experience in vaccine and antibody development, Dr. Nabors is expected to advance the company's programs, particularly ATI-1701 for tularemia and ATI-1801 for cutaneous leishmaniasis. Both candidates could qualify for FDA Priority Review Voucher upon approval. The announcement comes as Dr. Nabors represents Appili at the World Vaccine Congress in Washington, D.C., from April 3rd to 6th, 2023, to engage with industry leaders and trends in vaccine development.

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) has announced an amended loan agreement with Long Zone Holdings Inc. to receive an additional C$2.5 million as part of a secured loan to support working capital. This second tranche supplements the first tranche of US$3.6 million from the original loan agreement dated March 25, 2022. The total loan is due by March 15, 2025, with an interest rate of 11% per annum. The company expects to net C$2.2 million after fees. The agreement has been conditionally approved by the Toronto Stock Exchange.

Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) reported its Q3 fiscal 2023 results, highlighting significant developments in its infectious disease and biodefense portfolio. The U.S. Department of Defense has approved approximately US$14 million funding for ATI-1701, a tularemia vaccine. The NDA for ATI-1501 has been accepted by the FDA, with a PDUFA date of September 23, 2023. Financially, the company reported a reduced net loss of $6.6 million for the nine months ending December 31, 2022, down from $21.8 million in the previous year, attributed to decreased research and development expenses. However, cash reserves fell to $1.4 million from $6.7 million.

Appili Therapeutics has appointed Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program.

Dr. Gelhaus brings over 20 years of expertise in infectious disease research, specifically on Francisella tularensis, while Baran has more than 22 years of experience in drug development and business operations.

The appointments come at a crucial time following recent funding from DTRA for the ATI-1701 program, aimed at developing a vaccine to combat serious biological threats.

Appili Therapeutics Inc. has announced a Notice of Allowance for new patent claims for ATI-1501, a liquid oral reformulation of the antibiotic metronidazole. This patent strengthens ATI-1501's position as a convenient alternative for patients who struggle with the bitter taste of current metronidazole tablets, which are widely prescribed for parasitic and bacterial infections. Appili and partner Saptalis Pharmaceuticals expect FDA approval for ATI-1501 by the end of 2023.

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) announced a significant funding boost from the U.S. Department of Defense (DOD) for its ATI-1701 vaccine project, receiving at least US$14 million over two years. This funding, a 40% increase from prior projections, will allow the company to advance its biodefense efforts against the high-priority biothreat of Francisella tularensis. Additionally, Dr. Don Cilla has been appointed as CEO and Dr. Armand Balboni as Chair of the Board, ensuring strong leadership for this critical initiative.

Appili Therapeutics (OTCQX: APLIF) announced a strategic reprioritization, focusing on three key programs: ATI-1701, ATI-1501, and ATI-1801. The company received over US$10 million in funding from the DTRA to advance ATI-1701, aiming for FDA approval by end of 2023. During Q2, the net loss was $4 million, down from $18.5 million year-over-year, reflecting decreased R&D expenses.

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) held its annual and special meeting of shareholders, where all proposed resolutions were approved. Key outcomes include the election of directors such as Ian Mortimer and Brian Bloom, with votes for Mortimer at 98.42%. Shareholders re-appointed PricewaterhouseCoopers as the independent auditor and approved amendments to the stock option plan to a rolling 10% structure. Further details on voting results are available on the Company’s SEDAR profile.